Discover a new way to find and share stories you'll love… Learn about Reading Desk

All Blogs / Industries / Medical / Pharmaceutical / Popular


R&D Cost for Generics is Zero. Nothing. Nada. Nilch. So Why are Their Prices Surging?

According to the latest estimate from Tufts economists, it now costs upwards of $2.6 billion to bring a new prescription drug to market (read "Cost to Bring a New Drug to Market Is $2.6 Billion According to Tufts - 3X More Than in 2003!"). Show More Summary

Virtual Covalent Screening

Covalent drugs have been a big item in R&D over the last few years, and I wrote here about covalent fragments. The whole topic of reactive groups in small molecules and their interaction with living systems and biomolecules is a complicated...Show More Summary

Amgen Claims It All

There's plenty of excitement about PCSK9, the latest LDL-lowering pathway to make it deep into the clinic. You can tell that companies (and investors) have high hopes for it, since it's heading right into a market that's dominated by generic statins. Show More Summary

Surprise? Once Again, FULs and AMP Final Rule Delayed

In what has become a semi-annual ritual, the Centers for Medicare & Medicaid Services (CMS) last night announced plans to delay the Federal Upper Limits (FUL) and the Final Rule on Covered Outpatient Drugs, a.k.a., the Average Manufacturer Price (AMP) Final Rule. Show More Summary

More From The Bottom of the Publishing Barrel

Now, if you want to get a paper published in a prestigious journal like The International Journal of Advanced Computer Technology, you'd better make sure that you're up to it. You'd better make sure that you have good stuff to report, and that the paper is worth a spot in a venue like that. Show More Summary

Sanofi Beats the Drum

We saw AstraZeneca talking about its upcoming onslaught of drug approvals the other day, and not to be outdone, Sanofi is doing the same. Actually, they're seeing AstraZeneca's puny bet and raising them: Sanofi says that they could have...Show More Summary

News Roundup, November 2014: Salix, Merck, Co-Pay Cards, Part D Preferred Networks, and an Insurance Cartoon

Here's a pre-Thanksgiving news roundup, to stretch your mind before stretching your stomach next week. In this issue: Stuffing—Salix Pharmaceuticals reminds investors why wholesaler agreements matter Pumpkin Pie (in the Face)—How Merck...Show More Summary

Bind's Attempts To Remake Chemotherapy

There's a lot of effort (and a lot of money) going into targeted nanoparticle drug delivery. And that's completely understandable, because the way we dose things now, with any luck, will eventually come to seem primitive. So you used...Show More Summary

Dear Practitioner, You Say?

Spam mail is evolving: this afternoon I had one purportedly from the American Medical Association, although it was definitely not sent from their domain. In slightly ungrammatical English (but a cut above many other spammers), it informs me that they're sharing a document with me on Google Docs, and invite me to click a link. Show More Summary

AstraZeneca: How Many Approvals, Again?

So AstraZeneca says that they're expecting "8 to 10 " approvals in 2015-2016. Has anyone ever done that? Even close? I take it that this whole press release is there to pump up investors and keep Pfizer from coming back and making another bid for them, but although the company does have a lot of stuff going on, this just seems wildly optimistic. Show More Summary

Cost to Bring a New Drug to Market Is $2.6 Billion According to Tufts - 3X More Than in 2003!

According to a new study by the Tufts Center for the Study of Drug Development (CSDD), which receives funding from the pharmaceutical industry, the estimated cost to develop a new Rx drug for marketing in the U.S. is $2,558 million or $2.6 billion (see press release). Show More Summary

Wait, We Didn't Tell You About That Endpoint?

Hmm. Via Twitter, we find this interesting example of moving the goalposts. NeoStem, a small stem-cell company, announced results the other day for a trial of their cardiac stem cell therapy. One bearish trader who'd been following them...Show More Summary

TMS Azide Explosions

There's been a lot of safety on the blog this week. One recent accident I haven't talked about is an azide explosion at Minnesota - C&E News, though, has plenty of coverage. Back in June, a grad student was injured when a batch of trimethylsilyl azide exploded - a 200 gram batch. Show More Summary

Chemical Myths

Several folks on my Twitter feed have mentioned a new book coming out from Springer, 100 Chemical Myths. I haven't seen a copy, but it's supposed to "deals with popular yet largely untrue misconceptions and misunderstandings relatedShow More Summary

How Not to Do It: NMR Magnets

Here's an NMR imaging blog with details of a recent problem in an Indian facility. Two people ended up stuck to the machine, pinned by an oxygen cylinder (!) that one of them brought into the room. Both sustained injuries. There areShow More Summary

Allergan Escapes Valeant

The Allergan / Valeant saga has come to an end, with Allergan fighting them off by doing a deal to be taken over by Actavis. No word yet on whether they'are going to let Allergan keep the invisible golf course. Valeant is, of course,...Show More Summary

Vytorin Actually Works

The data from the IMPROVE-IT trial on cardiovascular outcomes for Vytorin have been released. And the combination met the primary endpoint: fewer heart attacks and strokes compared to those already on statin therapy alone. Matthew Herper has an excellent roundup of the results and their context. Show More Summary

Fatalities at DuPont

As many readers will have heard, there was a fatal accident at a DuPont plant in the Houston area over the weekend. Four workers were killed by methyl mercaptan (methanethiol), and here's more on what happened. As is often the case,Show More Summary

The New York TImes on Drug Discovery

The New York Times Magazine has a piece on the current problems with drug discovery. I was interviewed by the author, and get I quoted at one point. Nothing in the article will amaze any regular reader here, but it's probably the first...Show More Summary

How Are Things at Princeton?

So how's the new chemistry building at Princeton working out? I last asked for comments four years ago, but I'm prompted to do so again by this post by Luysii, who has been hearing that the building isn't necessarily working out as planned. Show More Summary

Copyright © 2011 Regator, LLC